{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T15:56:40Z","timestamp":1777737400237,"version":"3.51.4"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> To date, the role of bridging intravenous thrombolysis before mechanical thrombectomy (MTE) is controversial but still recommended in eligible patients. Different doses of intravenous alteplase have been used for treating patients with acute ischemic stroke from large-vessel occlusion (LVO-AIS) in Asia, largely due to variations in the risks for intracerebral hemorrhage (ICH) and treatment affordability. Uncertainty exists over the potential benefits of treating low-dose alteplase, as opposed to standard-dose alteplase, prior to MTE among patients with LVO-AIS.<\/jats:p><jats:p><jats:bold>Aim:<\/jats:bold> The aim of the study was to compare outcomes of low- vs. standard-dose of bridging intravenous alteplase before MTE among LVO-AIS patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We performed a retrospective analysis of LVO-AIS patients who were treated with either 0.6 mg\/kg or 0.9 mg\/kg alteplase prior to MTE at a stroke center in Northern Vietnam. Multivariable logistic regression models, accounting for potential confounding factors including comorbidities and clinical factors (e.g., stroke severity), were used to compare the outcomes between the two groups. Our primary outcome was functional independence at 90 days following stroke (modified Rankin score; mRS \u2264 2). Secondary outcomes included any ICH incidence, early neurological improvement, recanalization rate, and 90-day mortality.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> We analyzed data of 107 patients receiving bridging therapy, including 73 with low-dose and 34 with standard-dose alteplase before MTE. There were no statistically significant differences between the two groups in functional independence at 90 days (adjusted OR 1.02, 95% CI 0.29\u20133.52) after accounting for potential confounding factors. Compared to the standard-dose group, patients with low-dose alteplase before MTE had similar rates of successful recanalization, early neurological improvement, 90-day mortality, and ICH complications.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> In the present study, patients with low-dose alteplase before MTE were found to achieve comparable clinical outcomes compared to those receiving standard-dose alteplase bridging with MTE. The findings suggest potential benefits of low-dose alteplase in bridging therapy for Asian populations, but this needs to be confirmed by further clinical trials.<\/jats:p>","DOI":"10.3389\/fneur.2021.653820","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T06:51:34Z","timestamp":1617951094000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Low-Dose vs. Standard-Dose Intravenous Alteplase in Bridging Therapy Among Patients With Acute Ischemic Stroke: Experience From a Stroke Center in Vietnam"],"prefix":"10.3389","volume":"12","author":[{"given":"Duy Ton","family":"Mai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viet Phuong","family":"Dao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van Chi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dang Luu","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien Dung","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan Trung","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quoc Viet","family":"Bui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha Quan","family":"Phan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quang Tho","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoang Kien","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anh Tuan","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quang Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phuc Duc","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoang","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoang Thi","family":"Phan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1161\/STR.0000000000000074","article-title":"2015 American heart association\/American stroke association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American heart association\/American stroke association","volume":"46","author":"Powers","year":"2015","journal-title":"Stroke"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1161\/STROKEAHA.120.030796","article-title":"Large vessel occlusion strokes after the DIRECT-MT and SKIP trials","volume":"51","author":"Nogueira","year":"2020","journal-title":"Stroke."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/WCO.0000000000000633","article-title":"Is intravenous thrombolysis still necessary in patients who undergo mechanical thrombectomy?","volume":"32","author":"Katsanos","year":"2019","journal-title":"Curr Opin Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1161\/STROKEAHA.117.017208","article-title":"Direct mechanical thrombectomy versus combined intravenous and mechanical thrombectomy in large-artery anterior circulation stroke: a topical review","volume":"48","author":"Fischer","year":"2017","journal-title":"Stroke."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1093\/med\/9780199687039.003.0067_update_001","article-title":"Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials","volume":"47","author":"Lees","year":"2016","journal-title":"Stroke."},{"key":"B6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12883-019-1341-3","article-title":"Intravenous fibrinolysis plus endovascular thrombectomy versus direct endovascular thrombectomy for anterior circulation acute ischemic stroke: clinical and infarct volume results","volume":"19","author":"Gamba","year":"2019","journal-title":"BMC Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2001123","article-title":"Endovascular thrombectomy with or without intravenous alteplase in acute stroke","volume":"382","author":"Yang","year":"2020","journal-title":"N Eng J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jama.2020.23523","article-title":"Effect of endovascular treatment alone vs. intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke: the DEVT randomized clinical trial","volume":"325","author":"Zi","year":"2021","journal-title":"JAMA."},{"key":"B9","doi-asserted-by":"publisher","first-page":"814","DOI":"10.26226\/morressier.5aeac941521e300021137fd4","article-title":"Mr clean-no iv: intravenous treatment followed by endovascular treatment versus direct endovascular treatment for acute ischemic stroke caused by a proximal intracranial occlusion","volume":"4","author":"LeCouffe","year":"2019","journal-title":"Eur Stroke J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/STR.0b013e318284056a","article-title":"Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart association\/American stroke association","volume":"44","author":"Jauch","year":"2013","journal-title":"Stroke."},{"key":"B11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/svn-2017-000112","article-title":"Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review","volume":"3","author":"Wang","year":"2018","journal-title":"Stroke Vasc Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart association\/American stroke association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"key":"B13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1161\/STR.0000000000000086","article-title":"Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke","volume":"47","author":"Demaerschalk","year":"2016","journal-title":"Stroke."},{"key":"B14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke."},{"key":"B15","unstructured":"Use of the alberta stroke program early CT score (ASPECTS) for assessing CT scans in patients with acute stroke153442\n            PexmanJH\n            BarberPA\n            HillMD\n            SevickRJ\n            DemchukAM\n            HudonME\n          11559501AJNR Am J Neuroradiol.222001"},{"key":"B16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/svn-2017-000135","article-title":"Guidelines for evaluation and management of cerebral collateral circulation in ischaemic stroke 2017","volume":"3","author":"Liu","year":"2018","journal-title":"Stroke Vasc Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1161\/STROKEAHA.118.020700","article-title":"Modified thrombolysis in cerebral infarction 2C\/thrombolysis in cerebral infarction 3 reperfusion should be the aim of mechanical thrombectomy","volume":"49","author":"Dargazanli","year":"2018","journal-title":"Stroke."},{"key":"B18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5853\/jos.2017.01578","article-title":"Low- versus standard-dose intravenous alteplase in the context of bridging therapy for acute ischemic stroke: a korean ENCHANTED study","volume":"20","author":"Kim","year":"2018","journal-title":"J Stroke."},{"key":"B19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2174\/1567202615666180717113526","article-title":"Recombinant tissue plasminogen activator in acute ischemic stroke patients receiving thrombectomy: standard or low dose therapy?","volume":"15","author":"Lin","year":"2018","journal-title":"Curr Neurovasc Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1177\/1747493019840932","article-title":"The randomized study of endovascular therapy with versus without intravenous tissue plasminogen activator in acute stroke with ICA and M1 occlusion (SKIP study)","volume":"14","author":"Suzuki","year":"2019","journal-title":"Int J Stroke."},{"key":"B21","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1177\/2516608520976275","article-title":"Bridging therapy and direct thrombectomy for acute ischemic stroke: a prospective cohort study","volume":"3","author":"Nguyen","year":"2020","journal-title":"J Stroke Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa1716405","article-title":"Tenecteplase versus alteplase before thrombectomy for ischemic stroke","volume":"378","author":"Campbell","year":"2018","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.653820\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T06:51:41Z","timestamp":1617951101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.653820\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":22,"alternative-id":["10.3389\/fneur.2021.653820"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.653820","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"article-number":"653820"}}